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Some cancer patients show accelerated growth of
pre-existing metastases after removal of the primary
tumor. The purpose of this study was to investigate
whether primary tumor-induced metastasis suppres-
sion can be mediated by thrombospondin-1 in mela-
noma. Human melanoma xenografts (D-12, R-18,
and U-25) were used as models of melanoma in
humans. Melanoma angiogenesis, lung colonization,
and spontaneous pulmonary metastasis were inhibi-
ted in mice bearing D-12, U-25, or thrombospon-
din-1 overexpressing R-18 tumors, which showed
high thrombospondin-1 expression and secreted
large quantities of thrombospondin-1 into the blood,
but not in mice bearing wild-type R-18 tumors,
which were negative for thrombospondin-1. D-12
tumors suppressed the growth of their own spon-
taneous metastases. The anti-angiogenic and anti-
metastatic effects of D-12 and U-25 tumors were
blocked in mice treated with thrombospondin-1
neutralizing antibody. Dormant avascular microco-
lonies having an elevated apoptotic activity were
seen in the lungs of mice bearing D-12 or U-25
tumors, whereas only neovascularized lung macro-
colonies were seen in control and antibody-treated
mice. This study suggests that some melanoma
patients may bene®t from combined local treatment
and long-term anti-angiogenic therapy involving
thrombospondin-1. Key words: angiogenesis inhibition/
melanoma/metastasis suppression/thrombospondin-1. J
Invest Dermatol 117:1042±1049, 2001
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rowth of metastases in regional and distant sites is the
major cause of death of cancer patients (Fidler and
Ellis, 1994). The probability that cancer patients
develop metastatic disease is reduced after surgical
removal of the primary tumor (Sugarbaker et al,
1977); however, in some patients surgical removal of the primary
tumor is followed by accelerated growth of pre-existing metastases
in secondary organ sites (Sugarbaker et al, 1977). Folkman (1995)
has proposed an interesting hypothesis to explain this phenomenon.
The hypothesis states that a primary tumor, although being capable
of promoting neovascularization in its own vascular network by
secreting angiogenesis stimulators, can inhibit neovascularization of
a metastasis by generating angiogenesis inhibitors, and is based on
the assumptions that the angiogenesis stimulators are in excess of
the angiogenesis inhibitors at the primary site and that the
angiogenesis inhibitors are in excess of the angiogenesis stimulators
at the metastatic site, owing to the primary tumor having a larger
mass than the metastasis and the angiogenesis inhibitors having a
longer half-life in the blood circulation than the angiogenesis
stimulators. Folkman's hypothesis is supported by theoretical
considerations (Ramanujan et al, 2000) and experimental data on
murine tumors (Holmgren et al, 1995). Thus, the neovasculariz-
ation and growth of Lewis lung carcinoma and T241 ®brosarcoma
spontaneous pulmonary metastases have been shown to be
inhibited by the primary tumor (Holmgren et al, 1995). The
inhibitory effect was found to be caused by angiostatin (O'Reilly
et al, 1994), a 38 kDa internal fragment of plasminogen, which in
the case of the Lewis lung carcinoma most likely was produced by
metalloelastase secreted by tumor-in®ltrating macrophages (Dong
et al, 1997).
Thrombospondin-1 (TSP-1), a 450 kDa trimeric glycoprotein
secreted by a wide variety of tumor types, is another potent
angiogenesis inhibitor that has been suggested to mediate primary
tumor-induced suppression of metastatic growth (Volpert et al,
1998). This protein inhibits tumor angiogenesis by inducing
apoptosis in endothelial cells by binding to the transmembrane
receptor CD36 (JimeÂnez et al, 2000), a mechanism that explains its
ability to prevent endothelial cells from responding to a wide
variety of angiogenesis stimulators, including vascular endothelial
growth factor (VEGF) and basic ®broblast growth factor (bFGF)
(Campbell et al, 1998). Studies of bladder carcinoma (Grossfeld et al,
1997) and melanoma (Grant et al, 1998) have suggested that the
expression of TSP-1 in tumors is associated with the mutational
status of the p53 tumor suppressor gene, i.e., tumors with wild-type
p53 are more likely to show high TSP-1 expression than tumors
with mutant p53. This suggestion is consistent with the observ-
ations that the p53 protein is a transcriptional activator of the
TSP-1 gene and that increased expression of wild-type p53 results
in increased expression of TSP-1 in ®broblasts (Dameron et al,
1994). TSP-1 expression has been shown to be an important
prognostic factor independent of tumor stage, lymph node status,
and histologic grade in the transitional cell carcinoma of the urinary
bladder (Grossfeld et al, 1997). Studies of experimental tumors
suggesting that primary tumors can suppress the growth of
metastases by secreting TSP-1 have been performed. Thus,
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HT1080 human ®brosarcomas growing subcutaneously in athymic
mice were shown to produce large quantities of TSP-1 and to
prevent induction of angiogenesis by bFGF-containing pellets
implanted in the mouse cornea and to inhibit lung colonization of
B16 murine melanoma cells inoculated in the mouse tail vein
(Volpert et al, 1998); however, experimental studies demonstrating
that primary tumors can secrete suf®cient quantities of TSP-1 to
inhibit the growth of their own spontaneous metastases have not
been reported so far. Such data have not been published for any
other angiogenesis inhibitor produced directly by parenchymal
tumor cells either.
Several human melanoma xenograft lines having retained
essential biologic features of the donor patients' tumors, including
organ-speci®c metastatic pattern and the capacity to induce
angiogenesis, have been established previously in our laboratory
(Rofstad, 1994). These tumor lines were used in this study to
demonstrate that the development of spontaneous pulmonary
metastases in human melanoma in mice can be suppressed by
TSP-1 secreted by the primary tumor.
MATERIALS AND METHODS
Cell lines Human melanoma cell lines (D-12, R-18, and U-25) with
wild-type p53 were used. They were established from large regional
subcutaneous metastases of patients admitted to the Norwegian Radium
Hospital as described elsewhere (Rofstad, 1994). D-12 and U-25 cells
show high expression of TSP-1, whereas the expression of TSP-1 in
R-18 cells is insigni®cant. The R-18 line has been subcloned, and a
subclone showing high TSP-1 expression has been established. Most cells
of both the parent, wild-type line, and the TSP-1 overexpressing
subclone have near-triploid chromosome numbers; the number of
chromosomes per cell has been found to range from 49 to 67 (median:
57) in the wild type and from 52 to 68 (median: 61) in the subclone.
The main difference between the karyotypes is that chromosome 15 is
trisomic in the majority of the cells of the subclone, whereas
chromosome 15 is absent in most cells of the wild type. All cell lines
were maintained in monolayer culture in RPMI 1640 (25 mM HEPES
and L-glutamine) supplemented with 13% bovine calf serum, 250 mg
penicillin per l, and 50 mg streptomycin per l. The cultures were
incubated at 37°C in a humidi®ed atmosphere of 5% CO2 in air, and
subcultured twice a week. The cell lines were veri®ed to be free from
Mycoplasma contamination.
TSP-1 expression in vitro The expression of TSP-1 in exponentially
growing monolayer cell cultures was studied by western blotting. The
cells were washed in phosphate-buffered saline and boiled in Laemmli
lysis buffer for 5 min. Proteins were separated by sodium dodecyl
sulfate±polyacrylamide gel electrophoresis and transferred to a poly-
vinylidene ¯uoride membrane. Membranes were incubated with anti-
human TSP-1 mouse monoclonal antibody [TSP Ab-4 (clone A6.1);
NeoMarkers, Union City, CA] for 60 min. Bound antibody was
detected by a biotin±streptavidin alkaline phosphatase staining procedure.
TSP-1 (Calbiochem, San Diego, CA) puri®ed from human platelets was
used as positive control. The speci®city of the antibody±antigen
interaction was con®rmed by the incubation of membranes in solutions
without primary antibody. Protein molecular weights were estimated by
using prestained standards according to the manufacturer's instructions
(sodium dodecyl sulfate±polyacrylamide gel electrophoresis standards;
Bio-Rad Laboratories, Hercules, CA).
Treatment with TSP-1 and TSP-1 neutralizing antibody in vitro
Possible anti-proliferative, apoptotic, or cytotoxic effects of TSP-1
(Calbiochem) and TSP-1 neutralizing antibody [TSP Ab-1 (clone A4.1);
NeoMarkers] were investigated in vitro. D-12 cells were cultured in
RPMI 1640 (25 mM HEPES and L-glutamine) supplemented with 13%
bovine calf serum, 250 mg penicillin per l, and 50 mg streptomycin per l
in the absence or presence of 5 mg TSP-1 per ml or 5 mg TSP-1
neutralizing antibody per ml for up to 8 d. The number of cells in the
cultures was determined 2, 4, 6, or 8 d after the cultures were initiated
by counting cells in a hemocytometer. Apoptotic cells were detected by
immuno¯uorescence using an apoptosis detection kit (Apotag; Oncor,
Gaithersburg, MD) based on the terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate-biotin nick end labeling method as
instructed by the manufacturer. The colony forming ef®ciency of the
cells was measured at the same time points by plating 200 cells in 25 cm2
culture ¯asks, incubating the cells at 37°C in a humidi®ed atmosphere of
5% CO2 in air for 10 d, and then counting colonies containing more
than 50 cells by using a stereomicroscope.
Mice Adult (8±12 wk of age) female BALB/C nu/nu mice, bred at the
Institute for Cancer Research (The Norwegian Radium Hospital, Oslo,
Norway), were used as host animals for xenografted tumors. The mice
were maintained under speci®c pathogen-free conditions at constant
temperature (24±26°C) and humidity (30±50%). Sterilized food and tap
water were given ad libitum. Animal care and experiments were
performed according to the guidelines of the National Animal Research
Authority and were approved by the Institutional Committee on
Research Animal Care.
Intradermal ¯ank tumors Approximately 3.5 3 105 melanoma cells
in 10 ml of Ca2+- and Mg2+-free Hanks' balanced salt solution (HBSS)
were inoculated intradermally in the ¯anks of mice by using a 100 ml
Hamilton syringe. The tumors were deposited above the subcutaneous
muscle tissue in the deeper part of the dermis. The dermis and the
subcutaneous muscle were in®ltrated and gradually replaced by malignant
tissue during tumor growth. Tumor volume (V) was calculated as
V = p/6 3 ab2, where a is the longer and b is the shorter of two
perpendicular diameters, measured with calipers. The histologic
appearance of the tumors has been described in detail previously
(Rofstad, 1994). The tumors of all lines express bFGF and show VEGF-
dependent angiogenesis (Rofstad and Halsùr, 2000). Moreover, D-12
tumors form spontaneous pulmonary metastases, whereas R-18 and U-25
tumors do not (Rofstad, 1994; Rofstad and Halsùr, 2000).
TSP-1 expression in vivo The expression of TSP-1 in tumors was
studied by immunohistochemistry, using an avidin±biotin immuno-
peroxidase method. Tumors were ®xed in phosphate-buffered 4%
paraformaldehyde. Anti-human TSP-1 rabbit polyclonal antibody (TSP
Ab-8; NeoMarkers) was used as the primary antibody. Controls included
omission of the primary antibody, incubation with normal rabbit
immunoglobulin or normal rabbit serum, and incubation with blocking
peptide before staining. The sections were counterstained with
hematoxylin.
The concentration of TSP-1 in mouse plasma was determined by
western blotting using puri®ed human platelet TSP-1 (Calbiochem) as a
standard. Samples of 35 mg of total plasma protein were resuspended in
loading buffer containing 7.5% b-mercaptoethanol and boiled for 5 min.
Proteins were separated by sodium dodecyl sulfate±polyacrylamide gel
electrophoresis and blotted to a polyvinylidene membrane. Membranes
were incubated with TSP Ab-4 (clone A6.1), and bound antibody was
detected by a biotin±streptavidin alkaline phosphatase staining procedure.
Angiogenesis assay The capacity of D-12 cells to induce angiogenesis
was assessed by an intradermal angiogenesis assay (Rofstad, 1994). A
100 ml Hamilton syringe was used to inoculate aliquots of 1.0 3 106
cells suspended in 10 ml of HBSS intradermally in the abdominal region
of mice (day 0). The mice were killed on day 5 after the cell
inoculation. Small vascularized tumors had developed in the inoculation
sites at that time. The skin around the inoculation sites was removed,
and the tumors were located with a dissecting microscope. The
capillaries in the dermis oriented toward the tumors were counted, and
the diameters of the tumors were measured, using an ocular with a scale.
The number of capillaries was corrected for the background, determined
after the injection of 10 ml of HBSS. The number of tumor-oriented
capillaries per tumor and the number of tumor-oriented capillaries per
millimeter of tumor circumference were used as parameters for D-12-
induced angiogenesis.
Experiments were performed in control mice, in mice bearing D-12,
R-18, or U-25 intradermal ¯ank tumors, and in mice treated with TSP-
1 or TSP-1 neutralizing antibody. Four doses of 50 mg of puri®ed
human platelet TSP-1 (Calbiochem) or four doses of 100 mg of anti-
human TSP-1 mouse monoclonal antibody (TSP Ab-1 (clone A4.1);
NeoMarkers) were given in intervals of 24 h. The ®rst dose was given
24 h after the inoculation of D-12 cells (day 1). The TSP-1 and TSP-1
antibody solutions were diluted in HBSS and administered to the mice
in volumes of 0.25 ml by i.p. injection.
Lung colonization assay The lung colonization ef®ciency of D-12
cells was assessed by inoculating aliquots of 1.0 3 106 cells suspended in
0.2 ml of HBSS into the lateral tail vein of mice. The mice were killed
and autopsied at predetermined times after the cell inoculation. The
lungs were removed, rinsed in HBSS, and ®xed in Bouin's solution for
24 h to facilitate the scoring of colonies. The number of macroscopic
surface colonies was determined by using a stereomicroscope.
Experiments were performed in control mice and in mice bearing D-12,
R-18, or U-25 intradermal ¯ank tumors.
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Spontaneous metastasis assay The capacity of D-12 tumors to form
spontaneous pulmonary metastases was assessed as described previously
(Rofstad and Halsùr, 2000). Brie¯y, primary tumors were initiated by
inoculating aliquots of 3.5 3 105 cells suspended in 10 ml of HBSS
intradermally into the left ¯anks of mice. The tumors were removed
surgically at predetermined times, and the wounds were closed with
surgical clips. The mice were killed and autopsied at predetermined
times or when moribund. The lungs were examined for the presence of
macroscopic surface metastases as described above. Experiments were
performed in control mice, in mice bearing R-18 or U-25 intradermal
tumors in the right ¯anks, and in mice treated with TSP-1 neutralizing
antibody. TSP Ab-1 (clone A4.1) was administered to the mice in daily
doses of 100 mg as described above.
Histologic examinations of lung colonies and metastases Lungs
were snap-frozen in liquid nitrogen or ®xed in phosphate-buffered 4%
paraformaldehyde. The mitotic frequency of the parenchymal melanoma
cells in lung colonies and spontaneous pulmonary metastases was scored
in sections stained with hematoxylin and eosin. Apoptotic cells were
detected by immunohistochemistry, using an in situ apoptosis detection
kit (Apotag; Oncor, Gaithersburg, MD) based on the terminal
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin
nick end labeling method. Brie¯y, a solution of 30% terminal
deoxynucleotidyl transferase was applied at 37°C for 30 min to link
deoxyuridine triphosphate-digoxigenin to the 3¢-hydroxy ends of
fragmented DNA. Anti-digoxigenin peroxidase conjugate was applied for
30 min to detect labeled nucleotides. Diaminobenzidine was used as
chromogen. Negative controls received no terminal deoxynucleotidyl
transferase. To avoid erroneous identi®cation of apoptotic cells because
of light staining of necrotic cells, only brown-stained nuclei with
morphologic characteristics associated with apoptosis were scored as
apoptotic. Parallel sections were used for immunohistochemical detection
of endothelial cells, using an avidin±biotin immunoperoxidase method.
Anti-mouse CD31 rat monoclonal antibody (MEC 13.3; Research
Diagnostics, Flanders, NJ) was used as primary antibody. Controls
included omission of the primary antibody and incubation with blocking
peptide before staining. Immunostained sections were counterstained
with hematoxylin. Apoptotic frequencies of parenchymal melanoma cells
and tumor-associated endothelial cells were determined by examining
histologic sections at a magni®cation of 3 400.
Statistical analysis Data are presented as arithmetic mean 6 SEM.
Statistical comparisons of data were performed by one-way ANOVA under
conditions of normality and equal variance. Under other conditions,
comparisons were performed by nonparametric analysis using the
Kruskal±Wallis one-way ANOVA on ranks. When signi®cant differences
were found, the Bonferroni method (parametric tests) or the Dunnett
method (nonparametric tests) was used to identify data sets that differed
from control data. p < 0.05 was considered signi®cant. All p-values were
determined from two-sided tests. The statistical analysis was performed
by using SigmaStat statistical software (Jandel Scienti®c GmbH, Erkrath,
Germany).
RESULTS
Experiments with D-12, U-25, and wild-type R-18 cells and
tumors D-12 and U-25 cells showed signi®cant expression of
TSP-1, whereas R-18 cells did not, as revealed by western blot
analysis of cells derived from exponentially growing monolayer
cultures (Fig 1A). The expression of TSP-1 was higher in U-25
cells than in D-12 cells in ®ve of ®ve independent experiments.
Immunohistochemical preparations showed that D-12 and U-25
tumors stained positive for TSP-1, whereas R-18 tumors were
negative (Fig 1B). The TSP-1 staining was relatively
homogeneous within a tumor and appeared to be localized in the
cytoplasm of the cells. Although a few clusters of negative cells
were observed in some U-25 tumors, U-25 tumors generally
showed stronger staining than D-12 tumors. Moreover, D-12 and
U-25 tumors showed signi®cant secretion of TSP-1, whereas R-18
tumors did not. The TSP-1 concentrations in the plasma of mice
bearing 800±1000 mm3 tumors were 4 6 1 mg per ml (D-12;
n = 8) and 6 6 1 mg per ml (U-25; n = 7). TSP-1 could not be
detected in the plasma of control mice and mice bearing 800±
1000 mm3 R-18 tumors.
Treatment with TSP-1 or TSP-1 neutralizing antibody had no
anti-proliferative, apoptotic, or cytotoxic effects on D-12 cells; the
total number of cells and their apoptotic frequency were not
signi®cantly different in treated and control cultures (p > 0.05) and
the colony forming ef®ciency of treated cells was not signi®cantly
different from that of control cells (p > 0.05), irrespective of
treatment (data not shown).
Experiments were designed to investigate whether D-12, R-18,
or U-25 intradermal ¯ank tumors secreted suf®cient quantities of
TSP-1 to inhibit D-12-induced angiogenesis, lung colonization of
D-12 cells, or spontaneous pulmonary metastasis of D-12 tumors.
Figure 1. D-12 and U-25 show TSP-1 expression in vitro and
in vivo, whereas R-18 does not. (A) Western blot showing the
expression of TSP-1 in exponentially growing D-12, R-18, and U-25
monolayer cell cultures. Proteins from 5.0 3 105 cells were loaded into
each lane. The arrow to the left indicates the TSP-1 speci®c band. The
arrow to the right indicates the position of a standard with a known
molecular weight of 203 kDa. (B) Immunohistochemical preparations of
D-12, R-18, and U-25 tumors stained with anti-TSP-1 antibody by an
avidin±biotin immunoperoxidase method. The sections were
counterstained with hematoxylin. Scale bars: 10 mm.
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The results of the angiogenesis experiments are presented in Fig 2,
which shows D-12-induced angiogenesis expressed as the number
of tumor-oriented capillaries per tumor for the nine groups of mice
included in the experiments. The number of D-12-induced
capillaries was higher in control mice, i.e., mice without D-12,
R-18, or U-25 ¯ank tumors (group 1), than in mice treated with
TSP-1 (group 2; p = 0.035), mice bearing D-12 tumors (group 3;
p = 0.027), and mice bearing U-25 tumors (group 4; p = 0.020).
Mice bearing R-18 tumors (group 5) and control mice showed
numbers of D-12-induced capillaries that were not different
(p > 0.05). The number of D-12-induced capillaries was lower in
control mice than in mice treated with TSP-1 neutralizing
antibody, irrespective of whether the mice were without ¯ank
tumors (group 6; p = 0.035) or were bearing D-12 tumors (group
7; p = 0.045), U-25 tumors (group 8; p = 0.016), or R-18 tumors
(group 9; p = 0.0089). Similar results and identical conclusions
were achieved by expressing D-12-induced angiogenesis as the
number of tumor-oriented capillaries per millimeter of tumor
circumference (data not shown).
Intradermal ¯ank tumors also in¯uenced the lung colonization
ef®ciency of D-12 cells (Fig 3). Eight groups of mice were
included in the experiments (Fig 3A), and the number of
macroscopic surface lung colonies per mouse was used as a
parameter for lung colonization ef®ciency (Fig 3B). The lung
colonization ef®ciencies in control mice, i.e., mice without D-12,
R-18, or U-25 ¯ank tumors, examined 3 wk (group 1) or 6 wk
(group 2) after the inoculation of D-12 cells were not different
(p > 0.05). Control mice showed a higher lung colonization
ef®ciency than mice bearing D-12 tumors during the whole
experimental period of 3 wk (group 3; p = 0.0019), mice bearing
U-25 tumors during the whole experimental period of 3 wk (group
4; p = 0.0031), and mice bearing U-25 tumors during the whole
experimental period of 6 wk (group 5; p = 0.000062). Mice that
had their D-12 tumors removed 3 wk after the inoculation of D-12
cells and were examined for lung colonies 3 wk later (group 6)
showed a lung colonization ef®ciency that was higher than that of
the mice in group 3 (p = 0.00071) and not different from those of
the mice in the two control groups (p > 0.05). Similarly, mice that
had their U-25 tumors removed 3 wk after the inoculation of D-12
cells and were examined for lung colonies 3 wk later (group 7)
showed a lung colonization ef®ciency that was higher than those of
the mice in group 4 (p = 0.00055) and group 5 (p = 0.00014) and
not different from those of the mice in the two control groups
(p > 0.05). The lung colonization ef®ciencies in control mice and
mice bearing R-18 tumors during the whole experimental period
of 3 wk (group 8) were not different (p > 0.05).
The development of spontaneous D-12 pulmonary metastases
was also in¯uenced differently by R-18 and U-25 intradermal ¯ank
tumors (Fig 4). Seven groups of mice were included in the
experiments (Fig 4A), and the percentage of mice that developed
macroscopic surface metastases was used as a parameter for
metastatic frequency (Fig 4B). The D-12 primary tumors were
removed 4 wk after they were initiated in all experimental groups.
Control mice, i.e., mice without R-18 or U-25 ¯ank tumors,
examined for metastatic status 4 wk (group 1) or 8 wk (group 2)
after the removal of the primary tumors showed metastatic
frequencies that were not different (p > 0.05). The metastatic
frequency was higher in control mice than in mice bearing U-25
tumors during the whole experimental period until they were
examined for metastatic status 4 wk (group 3; p = 0.0084) or 8 wk
(group 4; p = 0.0017) after the removal of the D-12 primary
tumors. Mice that had their U-25 tumors removed 4 wk after the
removal of the D-12 primary tumors and were examined for
metastatic status 4 wk later (group 5) showed a metastatic frequency
that was higher than those of the mice in group 3 (p = 0.0038) and
group 4 (p = 0.0017) and not different from those of the mice in
the two control groups (p > 0.05). Similarly, mice that were
bearing U-25 tumors during the whole experimental period until
they were examined for metastatic status 8 wk after the removal of
the D-12 primary tumors and were treated daily with TSP-1
neutralizing antibody the last 4 wk before they were examined for
metastatic status (group 6) showed a metastatic frequency that was
higher than those of the mice in group 3 (p = 0.0084) and group 4
(p = 0.0038) and not different from those of the mice in the two
control groups (p > 0.05). The metastatic frequency of mice
bearing R-18 tumors during the whole experimental period until
they were examined for metastatic status 4 wk after the removal of
the D-12 primary tumors (group 7) was not different from that of
control mice (p > 0.05). The volumetric growth rate of the D-12
primary tumors was not in¯uenced signi®cantly by the R-18 or
U-25 tumors (data not shown). It was con®rmed experimentally
that R-18 and U-25 ¯ank tumors did not give rise to spontaneous
pulmonary metastases.
Moreover, D-12 primary tumors secreted suf®cient quantities of
TSP-1 to inhibit the growth of their own spontaneous pulmonary
metastases (Fig 5). Four groups of mice were included in the
experiments (Fig 5A), and as above, the percentage of mice that
developed macroscopic surface metastases was used as a parameter
for metastatic frequency (Fig 5B). Control mice, i.e., mice bearing
D-12 primary tumors during the whole experimental period until
they were examined for metastatic status 5 wk after the primary
tumors were initiated (group 1), showed a lower metastatic
frequency than mice that had their primary tumors removed
2 wk after they were initiated and were examined for metastatic
status 3 wk later (group 2; p = 0.025), mice bearing the primary
tumors for 5 wk that were treated daily with TSP-1 neutralizing
antibody the last 3 wk before they were examined for metastatic
Figure 2. D-12-induced angiogenesis is inhibited by D-12 and
U-25 ¯ank tumors, but not by R-18 ¯ank tumors. Aliquots of
1.0 3 106 D-12 cells were inoculated intradermally in the abdominal
region of female BALB/c-nu/nu mice for evocation of angiogenesis and
tumor formation (day 0). The mice were bearing 800±1000 mm3 D-12,
R-18, or U-25 intradermal tumors in the right ¯anks or were without
¯ank tumors. Mice treated with TSP-1 were given four doses of 50 mg
(days 1±4). Mice treated with TSP-1 neutralizing antibody were given
four doses of 100 mg (days 1±4). D-12-induced angiogenesis was
quanti®ed by counting the capillaries in the dermis oriented toward the
tumors formed in the abdominal region (day 5). The plot shows the
number of tumor-oriented capillaries per tumor in the nine groups of
mice included in the experiments. Columns and bars represent mean
values and standard errors of 20 tumors. Group 1: Control mice. Group
2: Mice treated with TSP-1. Group 3: Mice bearing D-12 tumors.
Group 4: Mice bearing U-25 tumors. Group 5: Mice bearing R-18
tumors. Group 6: Mice treated with TSP-1 neutralizing antibody. Group
7: Mice bearing D-12 tumors treated with TSP-1 neutralizing antibody.
Group 8: Mice bearing U-25 tumors treated with TSP-1 neutralizing
antibody. Group 9: Mice bearing R-18 tumors treated with TSP-1
neutralizing antibody.
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status (group 3; p = 0.043), and mice that had their primary tumors
removed 5 wk after they were initiated and were examined for
metastatic status 3 wk later (group 4; p = 0.015). The metastatic
frequencies of the mice in the latter three groups were not different
(p > 0.05).
Histologic examinations of lungs of mice used in lung
colonization experiments revealed microcolonies of melanoma
cells in mice that were bearing D-12 or U-25 ¯ank tumors during
the whole experimental period until the lungs were removed, i.e.,
groups 3±5 in Fig 3. The lung microcolonies were seen either as
perivascular cuffs of ®ve to 10 cell layers or as pleural surface
colonies of two to four cell layers. Immunohistochemical staining
with antibody against CD31 showed no evidence of neovascular-
ization within the microcolonies. In contrast, lungs of control mice,
i.e., groups 1 and 2 in Fig 3, lungs of mice bearing D-12 or U-25
tumors that were removed 3 wk before the lungs were removed,
i.e., groups 6 and 7 in Fig 3, and lungs of mice bearing R-18
tumors, i.e., group 8 in Fig 3, showed only highly neovascularized
macrocolonies. Angiogenic activity was detected adjacent to
microcolonies as well as macrocolonies. The apoptotic activity
differed between macrocolonies and microcolonies, as revealed by
the analysis of ®ve pairs of lungs from each of the eight
experimental groups. The frequency of apoptotic melanoma cells
was higher in the microcolonies of groups 3±5 (5.2 6 1.4%) than
in the macrocolonies of groups 1 and 2 (0.8 6 0.3%; p = 0.0068)
and groups 6±8 (0.7 6 0.3%; p = 0.0020). Moreover, the apoptotic
frequency of the endothelial cells adjacent to the microcolonies of
groups 3±5 (19.1 6 3.4%) was higher than those of the endothelial
cells adjacent to the macrocolonies of groups 1 and 2 (7.9 6 1.8%;
p = 0.019) and groups 6±8 (8.5 6 2.2%; p = 0.013). In contrast,
the frequency of mitotic melanoma cells in the microcolonies of
groups 3±5 (1.0 6 0.2%) was not signi®cantly different from those
in the macrocolonies of groups 1 and 2 (0.9 6 0.2%; p > 0.05) and
groups 6±8 (1.1 6 0.2%; p > 0.05). Corresponding results were
achieved by subjecting the lungs of mice used in spontaneous
pulmonary metastasis experiments to histologic examinations.
Experiments with TSP-1 overexpressing and wild-type R-18
tumors Tumors initiated from the TSP-1 overexpressing R-18
subclone were not able to grow beyond a volume of 300±
500 mm3. The TSP-1 overexpressing R-18 tumors were poorly
vascularized, developed extensive necrotic regions, and showed
substantially stronger TSP-1 immunostaining than did D-12 and
U-25 tumors (Fig 6A). In contrast, wild-type R-18 cells
developed well vascularized tumors without necrosis that stained
negative for TSP-1 (Fig 6B). The concentration of TSP-1 in the
plasma of mice bearing 300±500 mm3 TSP-1 overexpressing R-18
tumors was 8 6 2 mg per ml (n = 5), which is higher than that in
the plasma of mice bearing 800±1000 mm3 D-12 or U-25 tumors
by factors of approximately 2.0 and 1.3, respectively.
Two experiments were performed to investigate whether D-12-
induced angiogenesis and D-12 lung colonization also could be
inhibited by TSP-1 overexpressing R-18 tumors. In each experi-
ment, aliquots of 1.0 3 106 D-12 cells were inoculated intrader-
mally in the abdominal region or intravenously in the tail vein in 10
mice bearing 300±500 mm3 TSP-1 overexpressing R-18 tumors
and in 10 control mice bearing 300±500 mm3 wild-type R-18
tumors. TSP-1 overexpressing R-18 tumors prevented D-12-
induced angiogenesis and D-12 lung colonization completely;
neither angiogenesis nor lung colonies could be detected in the
mice bearing TSP-1 overexpressing R-18 tumors. The angio-
genesis and the lung colonization in the control mice were
consistent with the control data in Figs 2 and 3. Moreover,
Figure 3. The lung colonization ef®ciency of D-12 cells is
inhibited by D-12 and U-25 ¯ank tumors, but not by R-18 ¯ank
tumors. Aliquots of 1.0 3 106 D-12 cells were inoculated intravenously
in female BALB/c-nu/nu mice for formation of lung colonies. The mice
were bearing D-12, R-18, or U-25 intradermal tumors in the right
¯anks or were without ¯ank tumors. The lungs of the mice were
removed at predetermined times and examined for the presence of
macroscopic surface colonies. (A) Schematic model of the experimental
protocol. The ¯ank tumors were initiated 1 wk (D-12), 4 wk (R-18), or
6 wk (U-25) before the intravenous inoculation of D-12 cells (week 0).
They had reached volumes of 10±20 mm3 (D-12), 100±150 mm3 (R-
18), and 30±50 mm3 (U-25) at week 0, volumes of 800±1000 mm3 (D-
12), 800±1200 mm3 (R-18), and 150±250 mm3 (U-25) at week 3, and
volumes of 800±1200 mm3 (U-25) at week 6. (B) Number of D-12 lung
colonies per mouse in the eight groups of mice included in the
experiments. Columns and bars represent mean values and standard
errors of 40 mice. Group 1: Control mice, i.e., mice without D-12, R-
18, or U-25 tumors; lung colonies were counted 3 wk after the
inoculation of D-12 cells. Group 2: Control mice, i.e., mice without D-
12, R-18, or U-25 tumors; lung colonies were counted 6 wk after the
inoculation of D-12 cells. Group 3: Mice bearing D-12 tumors during
the whole experimental period; lung colonies were counted 3 wk after
the inoculation of D-12 cells. Group 4: Mice bearing U-25 tumors
during the whole experimental period; lung colonies were counted 3 wk
after the inoculation of D-12 cells. Group 5: Mice bearing U-25 tumors
during the whole experimental period; lung colonies were counted 6 wk
after the inoculation of D-12 cells. Group 6: Mice bearing D-12 tumors
that were removed 3 wk after the inoculation of D-12 cells; lung
colonies were counted 6 wk after the inoculation of D-12 cells. Group
7: Mice bearing U-25 tumors that were removed 3 wk after the
inoculation of D-12 cells; lung colonies were counted 6 wk after the
inoculation of D-12 cells. Group 8: Mice bearing R-18 tumors during
the whole experimental period; lung colonies were counted 3 wk after
the inoculation of D-12 cells.
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aliquots of 3.5 3 105 and 1.0 3 106 D-12 cells were not able to
give rise to macroscopic tumor growth or spontaneous pulmonary
metastases when inoculated intradermally in the left ¯anks of mice
bearing 300±500 mm3 TSP-1 overexpressing R-18 tumors in the
right ¯anks.
DISCUSSION
The experiments reported here show that D-12 lung colonization
and spontaneous pulmonary metastasis were suppressed in mice
bearing D-12, U-25, or TSP-1 overexpressing R-18 intradermal
¯ank tumors. The observation that D-12 primary tumors inhibited
the growth of their own spontaneous metastases is particularly
interesting, suggesting that BALB/c-nu/nu mice bearing D-12
tumors model patients who show accelerated metastatic growth in
regional or distant organ sites following surgical removal of the
primary tumor (Sugarbaker et al, 1977).
The anti-metastatic effect of D-12, U-25, and TSP-1 over-
expressing R-18 ¯ank tumors was most likely mediated by TSP-1,
as mice bearing D-12, U-25, or TSP-1 overexpressing R-18
tumors showed high blood plasma concentrations of TSP-1, and
the effect was blocked in mice treated with neutralizing antibody
against TSP-1. Moreover, D-12 lung colonization and spontaneous
metastasis were not suppressed by wild-type R-18 tumors, which
stained negative for TSP-1 and did not secrete TSP-1 into the
blood circulation. The possibility that other inhibitors also were
involved cannot be excluded; however, angiostatin (O'Reilly et al,
1994), a potent angiogenesis inhibitor shown to suppress the
neovascularization and growth of Lewis lung carcinoma and T241
®brosarcoma metastases (Holmgren et al, 1995), was probably not
involved, as angiostatin could not be detected in the serum of mice
bearing 800±1000 mm3 D-12 or U-25 ¯ank tumors by western
blotting, using a speci®c anti-mouse angiostatin rabbit monoclonal
antibody (unpublished data).
TSP-1 is a multifunctional protein that regulates attachment,
migration, invasion, and differentiation of various cell types,
promotes chemotaxis and haptotaxis, and exerts anti-proliferative
and anti-angiogenic effects in vitro and in vivo (Bornstein, 1995).
Several observations suggest that the TSP-1-mediated metastasis
suppression seen in this study was a result of its anti-angiogenic
activity. First, D-12-induced angiogenesis in an intradermal
secondary site was inhibited in mice bearing D-12, U-25, or
TSP-1 overexpressing R-18 ¯ank tumors and in mice treated with
exogenous TSP-1. Second, D-12 lung microcolonies were seen in
mice bearing D-12 or U-25 ¯ank tumors during lung colonization
and spontaneous metastasis experiments, suggesting that it was
primarily the growth of microcolonies and not the seeding of
melanoma cells in the lungs that was inhibited. These micro-
colonies were nonvascularized and surrounded by endothelial cells
with an increased apoptotic activity. Moreover, the microcolonies
stayed dormant as long as the ¯ank tumors were present, and
developed into neovascularized macrocolonies after they were
removed. Third, treatment with TSP-1 or TSP-1 neutralizing
antibody in vitro had no anti-proliferative, apoptotic, or cytotoxic
effects on D-12 cells. Our conclusion is consistent with the
observation that xenotransplanted tumors of human A431
carcinoma cells transfected with TSP-1 showed lower volumetric
growth rate, lower vascular density, and larger necrotic regions than
nontransfected control tumors (Streit et al, 1999).
Figure 4. The development of spontaneous D-12 metastases is
inhibited by U-25 ¯ank tumors, but not by R-18 ¯ank tumors.
D-12 primary tumors giving rise to spontaneous pulmonary metastases
were initiated in the left ¯anks of female BALB/c-nu/nu mice. The mice
were bearing R-18 or U-25 intradermal tumors or were without tumors
in the right ¯anks. The lungs of the mice were removed at
predetermined times and examined for the presence of macroscopic
surface metastases. (A) Schematic model of the experimental protocol.
The D-12 primary tumors were initiated at week 0 and had reached
volumes of 800±1000 mm3 at week 4. The R-18 and U-25 ¯ank tumors
were initiated at the same time as the D-12 primary tumors and had
reached volumes of 100±150 mm3 (R-18) and 10±20 mm3 (U-25) at
week 4, volumes of 1000±1500 mm3 (R-18) and 100±200 mm3 (U-25)
at week 8, and volumes of 800±1200 mm3 (U-25) at week 12. (B)
Percentage of mice that developed spontaneous D-12 metastases in the
seven groups of mice included in the experiments. Columns and bars
represent mean values and standard errors of four independent
experiments involving 10 mice each. Group 1: Control mice, i.e., mice
without R-18 or U-25 tumors; metastatic status was assessed 4 wk after
the D-12 primary tumors were removed. Group 2: Control mice, i.e.,
mice without R-18 or U-25 tumors; metastatic status was assessed 8 wk
after the D-12 primary tumors were removed. Group 3: Mice bearing
U-25 tumors during the whole experimental period of 8 wk; metastatic
status was assessed 4 wk after the D-12 primary tumors were removed.
Group 4: Mice bearing U-25 tumors during the whole experimental
period of 12 wk; metastatic status was assessed 8 wk after the D-12
primary tumors were removed. Group 5: Mice bearing U-25 tumors that
were removed 4 wk after the D-12 primary tumors were removed;
metastatic status was assessed 8 wk after the D-12 primary tumors were
removed. Group 6: Mice bearing U-25 tumors during the whole
experimental period of 12 wk; metastatic status was assessed 8 wk after
the D-12 primary tumors were removed. The mice were treated with
daily doses of 100 mg of TSP-1 neutralizing antibody in weeks 8±12.
Group 7: Mice bearing R-18 tumors during the whole experimental
period of 8 wk; metastatic status was assessed 4 wk after the D-12
primary tumors were removed.
VOL. 117, NO. 5 NOVEMBER 2001 THROMBOSPONDIN-1 AND METASTASIS SUPPRESSION 1047
Folkman (1995) has hypothesized that large primary tumors can
suppress the growth of their metastases by secreting angiogenesis
inhibitors that, owing to a long half-life in the blood circulation,
will be in excess of angiogenesis stimulators at the metastatic site.
The data reported here are in full agreement with this hypothesis,
and suggest that primary tumor-induced metastasis suppression can
be mediated by TSP-1 in malignant melanoma. The angiogenesis
of D-12 and U-25 tumors is stimulated primarily by VEGF
(Rofstad and Halsùr, 2000), which has a half-life in blood of
approximately 3 min (Folkman, 1995; Ramanujan et al, 2000). The
half-life of TSP-1, on the other hand, is several hours (Volpert et al,
1998; Ramanujan et al, 2000). The high rate of TSP-1 secretion of
D-12 and U-25 tumors is possibly associated with their p53
mutational status, as melanomas with wild-type p53 generally show
higher expression of TSP-1 than melanomas with mutant p53
(Grant et al, 1998).
Our suggestion that metastasis suppression by the primary tumor
can be mediated by TSP-1 in melanoma is strengthened by a
comprehensive study by Volpert et al (1998). They showed that the
lung colonization of B16 murine melanoma cells inoculated into
the tail vein of athymic mice was inhibited by subcutaneous
HT1080 human ®brosarcomas secreting TSP-1. Moreover, our
suggestion is consistent with a recent clinical observation by
Crawford et al (1998), who reported rapid growth of cutaneous
metastases shortly after surgical resection of a TSP-1-secreting small
blue round cell primary tumor, possibly a primitive neuroecto-
dermal tumor, of a 2 mo old girl. Metastasis suppression by the
primary tumor may also be mediated by angiogenesis inhibitors
other than TSP-1, as angiogenesis in a secondary site has been
shown to be inhibited by tumors secreting angiostatin (O'Reilly et
Figure 5. The development of spontaneous D-12 metastases is
inhibited by the D-12 primary tumor. D-12 primary tumors giving
rise to spontaneous pulmonary metastases were initiated in the left ¯anks
of female BALB/c-nu/nu mice. The lungs of the mice were removed at
predetermined times and examined for the presence of macroscopic
surface metastases. (A) Schematic model of the experimental protocol.
The D-12 primary tumors were initiated at week 0 and had reached
volumes of 50±100 mm3 at week 2 and volumes of 1000±2000 mm3 at
week 5. (B) Percentage of mice that developed spontaneous D-12
metastases in the four groups of mice included in the experiments.
Columns and bars represent mean values and standard errors of four
independent experiments involving 10 mice each. Group 1: Mice
bearing D-12 primary tumors during the whole experimental period of
5 wk before metastatic status was assessed. Group 2: Mice bearing D-12
primary tumors that were removed after 2 wk; metastatic status was
assessed 3 wk after the primary tumors were removed. Group 3: Mice
bearing D-12 primary tumors during the whole experimental period of
5 wk before metastatic status was assessed. The mice were treated with
daily doses of 100 mg of TSP-1 neutralizing antibody in weeks 3±5.
Group 4: Mice bearing D-12 primary tumors that were removed after
5 wk; metastatic status was assessed 3 wk after the primary tumors were
removed.
Figure 6. Immunohistochemical preparations illustrating
differences between TSP-1 overexpressing and wild-type R-18
tumors. The sections were stained with anti-TSP-1 antibody by an
avidin±biotin immunoperoxidase method and counterstained with
hematoxylin. Scale bars: 150 mm. (A) TSP-1 overexpressing R-18 tumor.
The tumor showed strong TSP-1 staining and extensive necrotic regions.
The arrows point at a necrotic region. (B) Wild-type R-18 tumor. The
tumor showed no TSP-1 staining, no necrosis, and a high vessel density.
The arrows point at large vessels.
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al, 1994; Sckell et al, 1998) and transforming growth factor-b1
(Gohongi et al, 1999). It has indeed been shown that the growth of
spontaneous Lewis lung carcinoma metastases can be inhibited by
angiostatin produced by metalloelastase secreted by macrophages
having in®ltrated the primary tumor (O'Reilly et al, 1994;
Holmgren et al, 1995; Dong et al, 1997). An experimental study
demonstrating that the parenchymal cells of a primary tumor can
secrete suf®cient quantities of an angiogenesis inhibitor to suppress
the growth of spontaneous metastases from that tumor, however,
has not been reported until now.
Histologic examinations of lung colonies and spontaneous
metastases provided insight into the mechanism of the TSP-1-
mediated angiogenesis inhibition and metastasis suppression. The
endothelial cells adjacent to dormant microcolonies showed
increased apoptotic frequency, suggesting that TSP-1 inhibited
neovascularization of lung colonies by induction of apoptosis in
activated microvascular endothelial cells. This suggestion is con-
sistent with the observation that TSP-1 can induce apoptosis in
endothelial cells in vitro and in vivo by sequential activation of
CD36, p59fyn, caspase-3 like proteases, and p38 mitogen-activated
protein kinases (JimeÂnez et al, 2000). The mitotic frequency of the
D-12 melanoma cells was similar in dormant microcolonies and
neovascularized macrocolonies, suggesting that TSP-1 had no
signi®cant anti-proliferative effect on D-12 cells in vivo, consistent
with the in vitro data. In contrast, the D-12 apoptotic frequency was
higher in microcolonies than in macrocolonies. TSP-1 did not
induce apoptosis in D-12 cells in vitro, suggesting that the elevated
apoptotic activity in microcolonies was not a direct effect of
interaction between TSP-1 and D-12 cells. The high frequency of
apoptotic D-12 cells in microcolonies was more likely a result of
limited access to circulating apoptosis suppressive factors, such as
insulin-like growth factor-1 and platelet-derived growth factor
(Harrington et al, 1994), owing to the lack of adequate perfusion.
The dormancy of Lewis lung carcinoma and T241 ®brosarcoma
microcolonies in mouse lungs under angiogenesis suppression by
angiostatin has been studied in great detail by Holmgren et al
(1995), who found that tumor cell proliferation, measured by
bromodeoxyuridine incorporation and immunohistochemical
staining of proliferating cell nuclear antigen, was not signi®cantly
different in dormant and growing colonies, whereas the tumor cells
of dormant colonies exhibited more than a 3-fold higher incidence
of apoptosis. They concluded that tumor cell proliferation is
balanced by an equivalent rate of cell death in dormant metastases,
and suggested that angiostatin controls metastatic growth by
indirectly inducing apoptosis in tumor cells. The data in this
study are in full agreement with the conclusion of Holmgren et al
(1995) and suggest that the mechanism by which TSP-1 controls
metastatic dormancy is similar to that of angiostatin.
This study prompted us to speculate that micrometastases of
melanoma patients with large, wild-type p53 primary tumors may
escape dormancy after removal of the primary tumor, owing to the
disappearance of TSP-1 from the blood circulation. Therefore,
some melanoma patients may bene®t from combined local
treatment and long-term anti-angiogenic therapy involving TSP-1.
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